Core Viewpoint - The company plans to issue a total of 36 million placement shares, representing approximately 8.1% of the enlarged issued share capital post-completion, at a price of HKD 16.30 per share, which is a discount of about 9.5% compared to the closing price of HKD 18.01 on September 9 [1] Summary by Relevant Categories Fundraising Details - The total amount raised from the placement, assuming all shares are fully subscribed, will be HKD 586.8 million, with the estimated net proceeds from the placement being HKD 577.5 million [1] Use of Proceeds - Approximately 90% of the net proceeds will be allocated to research and development of clinical and pre-clinical pipeline projects, while about 10% will be used for general and corporate purposes [1]
来凯医药-B拟折让约9.5%配售3600万股 净筹约5.775亿港元